Literature DB >> 2079373

[Cefixime in urinary tract infections. (Specific studies and literature review)].

K G Naber1.   

Abstract

Cefixime, a new oral cephalosporin, is more active against enterobacteriaceae than the conventional oral cephalosporins. About 20% of the drug is excreted by the kidneys as active drug. Therefore, the treatment of urinary tract infection (UTI) by cefixime may be a good alternative. In two smaller uncontrolled and four larger, controlled (amoxicillin, co-trimoxazole) "western" studies as well as in eight Japanese studies the good efficacy of cefixime in uncomplicated UTI could be demonstrated. Because of its antibacterial spectrum in this kind of infection the therapy with cefixime can be initiated already prior to sensitivity testing. Concerning the treatment of acute pyelonephritis only few cases are reported. Good results, except in the case of Proteus mirabilis infection, could be achieved. In the treatment of complicated UTI our own controlled (norfloxacin) and 13 uncontrolled Japanese studies showed cefixime to be an effective antibiotic if infections are caused by sensitive strains. Since in complicated UTI also gram-positive and nonfermenting pathogens resistant to cefixime can be found, treatment should not be initiated without sensitivity testing. Concerning treatment of UTI in children only few, but promising, results are reported. The tolerance of cefixime was similar to that of the comparative drugs. The once daily dose (400 mg), however, showed a higher incidence of gastrointestinal adverse effects than a twice daily dose (200 mg). Therefore, the daily dose should be administered in two divided doses. In summary, cefixime proved to be a good alternative in the treatment of UTI.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2079373     DOI: 10.1007/BF01644632

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  10 in total

1.  Spectrum of bacterial pathogens in uncomplicated and complicated urinary tract infections.

Authors:  A Bauernfeind; K Naber; D Sauerwein
Journal:  Eur Urol       Date:  1987       Impact factor: 20.096

2.  [Spectrum of pathogens in patients with urinary tract infections from a clinical viewpoint].

Authors:  K Naber; A Bauernfeind; G Dietlein
Journal:  MMW Munch Med Wochenschr       Date:  1983-05-20

3.  A double-blind, multicenter, comparative study of the safety and efficacy of cefixime versus amoxicillin in the treatment of acute urinary tract infections in adult patients.

Authors:  A Iravani; G A Richard; D Johnson; A Bryant
Journal:  Am J Med       Date:  1988-09-16       Impact factor: 4.965

4.  Noncomparative, open label, multicenter trial of cefixime for treatment of bacterial pharyngitis, cystitis and pneumonia in pediatric patients.

Authors:  W L Risser; J S Barone; P A Clark; D L Simpkins
Journal:  Pediatr Infect Dis J       Date:  1987-10       Impact factor: 2.129

5.  [Comparative study of intravenous ceftriaxone followed by oral cefixime versus ceftriaxone alone in the treatment of severe upper urinary tract infections].

Authors:  B Regnier
Journal:  Presse Med       Date:  1989-10-11       Impact factor: 1.228

6.  [Efficacy and tolerability of cefixime in urinary tract infections in adults. A French multicentric study].

Authors:  J Modai
Journal:  Presse Med       Date:  1989-10-11       Impact factor: 1.228

7.  The pharmacokinetic and bactericidal characteristics of oral cefixime.

Authors:  D C Brittain; B E Scully; T Hirose; H C Neu
Journal:  Clin Pharmacol Ther       Date:  1985-11       Impact factor: 6.875

8.  Comparison of cefixime and co-trimoxazole in acute uncomplicated urinary tract infection. A double-blind general practice study.

Authors:  J Levenstein; P J Summerfield; S Fourie; G Brink; B Michaelides; E Murray; N Naidoo
Journal:  S Afr Med J       Date:  1986-10-11

9.  Comparative in vitro activity and beta-lactamase stability of FR 17027, a new orally active cephalosporin.

Authors:  H C Neu; N X Chin; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

10.  Cefixime versus trimethoprim/sulfamethoxazole in treatment of patients with acute, uncomplicated lower urinary tract infections.

Authors:  C E Cox
Journal:  Urology       Date:  1989-11       Impact factor: 2.649

  10 in total
  1 in total

1.  Cefixime versus prulifloxacin as a prophylactic treatment for prostate biopsy: a randomized study.

Authors:  Michael Samarinas; Konstantinos Skriapas; Iraklis Mitsogiannis; Stavros Gravas; Anastasios Karatzas; Vasileios Tzortzis
Journal:  Cent European J Urol       Date:  2020-10-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.